MARKETS / COMPANIES / ECONOMYRSS edition ↗
Dividend Brief
Market News

We are open to external innovation and collaborations in India: BMS EVP Cristian

7bbca2f9-3750-497c-a321-5ccfabe898f2 Hyderabad India has emerged as an important center for Bristol Myers Squibb’s (BMS) global operations. The company is integrating artificial intelligence into its development…

We are open to external innovation and collaborations in India: BMS EVP Cristian

7bbca2f9-3750-497c-a321-5ccfabe898f2 Hyderabad India has emerged as an important center for Bristol Myers Squibb’s (BMS) global operations. The company is integrating artificial intelligence into its development processes to improve efficiency, reduce costs and increase the probability of success in clinical trials. businessline spoke to Cristian Massacesi, MD, Executive Vice President, Chief Medical Officer and Head of Development, BMS on the role of Indian operations in global drug development, research priorities, AI adoption and the scope for collaborations. Excepts: What is the contribution of the Hyderabad centre to BMS’s global operations? Hyderabad is our biggest site in India, with around 3,000 people, of whom about 1,300 are in development. We also have teams in IT-, finance- and manufacturing-related functions. Bengaluru is our second important centre, focused on research, while Mumbai houses our commercial and clinical operations teams. Hyderabad is fully integrated into global development. Our global product teams include project leaders, clinical specialists, statisticians, pharmacologists and regulatory professionals working across locations. For a particular clinical trial, the programme leader may be in the US, while the statistician or clinical development team could be in Hyderabad. These teams work together across countries to advance drug development. What are the research and therapeutic areas of focus in India? Bengaluru has particular strength in small-molecule research, including oral drugs, tablets and pills. It is also beginning to work on large molecules and antibodies. In Hyderabad, our development teams support all therapeutic areas. BMS focuses on oncology and haematology, cell therapy, neuroscience, immunology and cardiovascular diseases. We have more than 40 clinical trials ongoing. Every new trial is assessed for feasibility in India, with the aim of bringing it here wherever possible. Our Mumbai-based operational team identifies hospitals and academic institutions that can participate and enrol patients. Can technology significantly reduce drug development costs and timelines? Of the 10 drugs that enter clinical trials, only one reaches approval. The attrition rate is more than 90 per cent. Development from clinical trials to approval can take 9-12 or 13 years, with costs ranging from $800 million to $2 billion for a drug. These costs are becoming unsustainable. Technology can help shorten timelines, improve clinical trial site selection, make studies smaller and faster, and reduce costs. More importantly, we need to improve the probability of success. At BMS, we are using data and language models to design better trials and predict outcomes. The bottleneck today is development, rather than research. How far has AI adoption progressed in drug discovery and development? AI is already helping in research by engineering drug candidates against identified targets. What earlier took weeks or months can now happen in days, and the candidates are of higher quality. In development, its integration is lower, particularly in predicting outcomes. We have embedded tools to optimise clinical trial assessments and costs. However, developing models that can better predict whether a drug will succeed may take another three to five years. We have collaborations with technology companies, including a recent deal with NVIDIA. Our employees have access to Claude. I use AI for around 30 per cent of my work. It helps teams complete repetitive tasks faster and spend more time on higher-level decisions. Will AI reduce employment in the pharmaceutical industry? I think AI will improve the quality of jobs. Repetitive activities such as programming and some data-management tasks can potentially be performed by machines. This will allow employees to focus on more strategic and intellectually stimulating work. AI can also bring information together and support better and faster decision-making. What is the scope for collaborations with Indian companies? We work with Syngene in research and development, including support for a clinical trial involving one of our immunology drugs. We are open to more collaborations with companies whose innovation aligns with our strategy. We cannot do everything internally; external innovation and partnerships are an important part of our model. How do you see the scale of BMS operations in India evolving? We have scaled up considerably and will continue to grow in research and development, though we are now managing the pace of expansion. Across Hyderabad, Bengaluru and Mumbai, our workforce is around 3,500-3,700. These are high-skilled jobs involving scientists, statisticians and physicians. India is an important country for us, and we expect the value of the innovation, investment, employment and ecosystem we bring to be recognised. What is the contribution of the Hyderabad centre to BMS’s global operations? Hyderabad is our biggest site in India, with around 3,000 people, of whom about 1,300 are in development. We also have teams in IT-, finance- and manufacturing-related functions. Bengaluru is our second important centre, focused on research, while Mumbai houses our commercial and clinical operations teams. Hyderabad is fully integrated into global development. Our global product teams include project leaders, clinical specialists, statisticians, pharmacologists and regulatory professionals working across locations. For a particular clinical trial, the programme leader may be in the US, while the statistician or clinical development team could be in Hyderabad. These teams work together across countries to advance drug development. What are the research and therapeutic areas of focus in India? Bengaluru has particular strength in small-molecule research, including oral drugs, tablets and pills. It is also beginning to work on large molecules and antibodies. In Hyderabad, our development teams support all therapeutic areas. BMS focuses on oncology and haematology, cell therapy, neuroscience, immunology and cardiovascular diseases. We have more than 40 clinical trials ongoing. Every new trial is assessed for feasibility in India, with the aim of bringing it here wherever possible. Our Mumbai-based operational team identifies hospitals and academic institutions that can participate and enrol patients. Can technology significantly reduce drug development costs and timelines? Of the 10 drugs that enter clinical trials, only one reaches approval. The attrition rate is more than 90 per cent. Development from clinical trials to approval can take 9-12 or 13 years, with costs ranging from $800 million to $2 billion for a drug. These costs are becoming unsustainable. Technology can help shorten timelines, improve clinical trial site selection, make studies smaller and faster, and reduce costs. More importantly, we need to improve the probability of success. At BMS, we are using data and language models to design better trials and predict outcomes. The bottleneck today is development, rather than research. How far has AI adoption progressed in drug discovery and development? AI is already helping in research by engineering drug candidates against identified targets. What earlier took weeks or months can now happen in days, and the candidates are of higher quality. In development, its integration is lower, particularly in predicting outcomes. We have embedded tools to optimise clinical trial assessments and costs. However, developing models that can better predict whether a drug will succeed may take another three to five years. We have collaborations with technology companies, including a recent deal with NVIDIA. Our employees have access to Claude. I use AI for around 30 per cent of my work. It helps teams complete repetitive tasks faster and spend more time on higher-level decisions. Will AI reduce employment in the pharmaceutical industry? I think AI will improve the quality of jobs. Repetitive activities such as programming and some data-management tasks can potentially be performed by machines. This will allow employees to focus on more strategic and intellectually stimulating work. AI can also bring information together and support better and faster decision-making. What is the scope for collaborations with Indian companies? We work with Syngene in research and development, including support for a clinical trial involving one of our immunology drugs. We are open to more collaborations with companies whose innovation aligns with our strategy. We cannot do everything internally; external innovation and partnerships are an important part of our model. How do you see the scale of BMS operations in India evolving? We have scaled up considerably and will continue to grow in research and development, though we are now managing the pace of expansion. Across Hyderabad, Bengaluru and Mumbai, our workforce is around 3,500-3,700. These are high-skilled jobs involving scientists, statisticians and physicians. India is an important country for us, and we expect the value of the innovation, investment, employment and ecosystem we bring to be recognised.

Source: The Hindu BusinessLine — Info-tech ↗

Figures reflect the source report and its stated period. This article is for information and is not investment advice.